세계의 환자 등록 소프트웨어 시장(-2030년) : 질환, 제품, 이용 사례, 최종 사용자 및 지역별

The global patient registry software market is expected to reach USD 3.61 billion by 2030 from USD 2.25 billion in 2025, at a CAGR of 9.8%. Healthcare systems are increasingly focused on capturing and analyzing patient data to enhance care quality and meet regulatory requirements. Patient registry software collects disease, procedure, and population data, facilitating clinical research and population health management. These platforms are vital for generating real-world evidence to support drug assessments and value-based care, ultimately reducing healthcare costs and driving market growth.

"The direct-to-patient registries segment is expected to witness the highest growth during the forecast period."

The patient registry software market is divided into direct-to-patient and site-based/clinical data registries. Direct-to-patient registries are expected to register the highest CAGR due to increased patient engagement, adoption of digital health tools (like ePRO and mobile apps), demand for real-world evidence from patients, and the rise of decentralized clinical trials that focus on patient-reported outcomes. Virtual platforms simplify data collection, easing the burden on healthcare providers and allowing for better longitudinal follow-up and diverse patient recruitment.

"The medical research & clinical studies segment held the largest share of the patient registry software market, by use case, in 2024."

In 2024, the medical research & clinical studies segment dominated the patient registry software market. This growth is largely driven by the increasing use of real-world data (RWD) and real-world evidence (RWE) for clinical trials and drug development. Patient registry software captures structured and longitudinal patient data, helping researchers analyze outcomes and monitor safety. The rise of personalized medicine and collaborations among life science companies, academic centers, and public health agencies further enhances the need for robust registry infrastructure. The shift toward decentralized trials and post-marketing surveillance also reinforces this segment's leading position.

"North America accounted for the largest share of the patient registry software market in 2024."

In 2024, North America held the largest share of the patient registry software market, driven by strong regulatory frameworks and early digital health adoption. Key players like MRO Corp and ImageTrend enhance competition and innovation. Federal initiatives, such as the US HHS's data modernization and the CDC's focus on chronic disease surveillance, increase the demand for registry platforms. Notably, in February 2025, Veradigm and HealthVerity partnered to integrate cardiovascular and metabolic data with HealthVerity's privacy-compliant platform, enabling comprehensive research on patient journeys. Additionally, in April 2024, ESO Solutions acquired Logis Solutions to improve data-driven emergency response, enhancing interoperability and patient outcomes. These developments solidify North America's leadership in patient registry software innovation and data integration.

The breakdown of primary participants is listed below:

• By Company Type: Tier 1 (45%), Tier 2 (30%), and Tier 3 (25%)
• By Designation: C-level Executives (42%), Directors (31%), and Others (27%)
• By Region: North America (35%), Europe (30%), Asia Pacific (25%), the Middle East & Africa (5%), and Latin America (5%)

Key Players in the Patient Registry Software Market

The key players in the patient registry software market include IBM (US), IQVIA Holdings Inc. (US), Health Catalyst Inc. (US), Oracle (US), UnitedHealth Group (US), Conduent Inc. (US), Elekta (Sweden), Dassault Systemes (France), EvidentIQ (Dacima Software Inc.) (Germany), MRO (Figmd, Inc.) (US), ImageTrend, Inc. (US), Global Vision Technologies, Inc. (US), Syneos Health (US), Veradigm LLC (US), ESO (US), Ordinal Data, Inc. (US), NEC Corporation (NEC Software Solutions UK Limited) (Japan), Cedaron Medical (US), Fivos Health (US), and Across Health (US).

Research Coverage

The report analyzes the patient registry software market. Its objective is to estimate the market size and future growth potential of various segments, categorized by product, registry type, use case, deployment model, end user, and region. Additionally, the report includes a competitive analysis of the key players in this market, featuring their company profiles, product offerings, recent developments, and key market strategies.

Reasons to Buy the Report

This report will help both established companies and new or smaller firms assess the market's current state, enabling them to capture a larger market share. Organizations that purchase this report can utilize one or more of the strategies outlined below to enhance their market positions.

This report provides insights on:

• Analysis of Key Drivers: Drivers (growing demand for real-world evidence (RWE) and rising incidence of chronic and rare diseases), restraints (high setup and operational costs and limited access in low-resource settings), opportunities [integration with AI and analytics tools and expanding use in decentralized clinical trials (DCTs)], and challenges (inconsistent data quality and completeness and limited workforce expertise) influencing the growth of the patient registry software market.
• Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product & service launches in the patient registry software market.
• Market Development: Comprehensive information on the lucrative emerging markets, products, use cases, registry types, deployment models, end users, and regions.
• Market Diversification: Exhaustive information about the product portfolios, growing geographies, recent developments, and investments in the patient registry software market.
• Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings, and capabilities of the leading players in the patient registry software market, such as IBM (US), IQVIA Holdings Inc. (US), Health Catalyst Inc. (US), Oracle (US), UnitedHealth Group (US), Conduent Inc. (US), and Elekta (Sweden).

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
• 1.3 MARKET SCOPE
  • 1.3.1 MARKET SEGMENTATION & REGIONAL SCOPE
  • 1.3.2 INCLUSIONS & EXCLUSIONS
  • 1.3.3 YEARS CONSIDERED
• 1.4 CURRENCY CONSIDERED
• 1.5 LIMITATIONS
• 1.6 STAKEHOLDERS
• 1.7 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

• 2.1 RESEARCH DATA
  • 2.1.1 SECONDARY DATA
    • 2.1.1.1 Key data from secondary sources
  • 2.1.2 PRIMARY DATA
    • 2.1.2.1 Key data from primary sources
    • 2.1.2.2 Breakdown of primary sources
• 2.2 RESEARCH METHODOLOGY DESIGN
• 2.3 MARKET SIZE ESTIMATION
• 2.4 MARKET BREAKDOWN & DATA TRIANGULATION
• 2.5 RESEARCH ASSUMPTIONS
  • 2.5.1 MARKET SIZING ASSUMPTIONS
  • 2.5.2 OVERALL STUDY ASSUMPTIONS
• 2.6 RISK ASSESSMENT
• 2.7 RESEARCH LIMITATIONS
  • 2.7.1 METHODOLOGY-RELATED LIMITATIONS
  • 2.7.2 SCOPE-RELATED LIMITATIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

• 4.1 PATIENT REGISTRY SOFTWARE MARKET OVERVIEW
• 4.2 NORTH AMERICA: PATIENT REGISTRY SOFTWARE MARKET, BY PRODUCT & REGION
• 4.3 PATIENT REGISTRY SOFTWARE MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
• 4.4 PATIENT REGISTRY SOFTWARE MARKET: DEVELOPED VS. EMERGING ECONOMIES

5 MARKET OVERVIEW

• 5.1 INTRODUCTION
• 5.2 MARKET DYNAMICS
  • 5.2.1 MARKET DYNAMICS
    • 5.2.1.1 Rising burden of chronic and rare diseases
    • 5.2.1.2 Shift toward value-based and patient-centered care
    • 5.2.1.3 Expansion of real-world evidence (RWE) and post-marketing surveillance needs
    • 5.2.1.4 Increasing use of digital health technologies and interoperable EHRs
    • 5.2.1.5 Government and regulatory incentives for registry implementation
  • 5.2.2 MARKET RESTRAINTS
    • 5.2.2.1 Shortage of trained and skilled resources
    • 5.2.2.2 High implementation and maintenance costs
  • 5.2.3 MARKET OPPORTUNITIES
    • 5.2.3.1 Expansion of population health management and outcomes tracking
    • 5.2.3.2 Rising demand for pregnancy and congenital anomaly registries for maternal-fetal safety monitoring
    • 5.2.3.3 Growing preference for subscription-based deployment models
  • 5.2.4 MARKET CHALLENGES
    • 5.2.4.1 Privacy- and data security-related concerns
    • 5.2.4.2 Reluctance to adopt advanced patient registry solutions
    • 5.2.4.3 Limited awareness among healthcare stakeholders
• 5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
• 5.4 INDUSTRY TRENDS
  • 5.4.1 STRENGTHENED FUNDING FOR PATIENT-CENTERED RESEARCH AND RARE DISEASE REGISTRIES
  • 5.4.2 RISE IN AUTOMATED DATA ENTRY AND REGISTRY INTELLIGENCE
  • 5.4.3 CLOUD-BASED REGISTRIES AND DECENTRALIZED ACCESS
• 5.5 ECOSYSTEM ANALYSIS
• 5.6 VALUE CHAIN ANALYSIS
• 5.7 TECHNOLOGY ANALYSIS
  • 5.7.1 KEY TECHNOLOGIES
    • 5.7.1.1 Electronic data capture (EDC) systems
    • 5.7.1.2 Cloud computing & SaaS architecture
    • 5.7.1.3 Data privacy & security technologies
  • 5.7.2 COMPLEMENTARY TECHNOLOGIES
    • 5.7.2.1 Electronic health record (EHR) systems
    • 5.7.2.2 Clinical trial management systems (CTMS)
  • 5.7.3 ADJACENT TECHNOLOGIES
    • 5.7.3.1 Digital therapeutics (DTx) platforms
    • 5.7.3.2 Wearable devices & remote monitoring tools
    • 5.7.3.3 Blockchain for health data management
• 5.8 REGULATORY ANALYSIS
  • 5.8.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 5.8.2 REGULATORY LANDSCAPE
    • 5.8.2.1 North America
    • 5.8.2.2 Europe
    • 5.8.2.3 Asia Pacific
    • 5.8.2.4 Middle East & Africa
    • 5.8.2.5 Latin America
• 5.9 PRICING ANALYSIS
  • 5.9.1 AVERAGE COST OF PATIENT REGISTRY SOFTWARE, BY END USER (2024)
  • 5.9.2 INDICATIVE PRICE OF PATIENT REGISTRY SOFTWARE, BY REGION (2024)
• 5.10 PORTER'S FIVE FORCES ANALYSIS
  • 5.10.1 INTENSITY OF COMPETITIVE RIVALRY
  • 5.10.2 BARGAINING POWER OF BUYERS
  • 5.10.3 THREAT OF SUBSTITUTES
  • 5.10.4 THREAT OF NEW ENTRANTS
  • 5.10.5 BARGAINING POWER OF SUPPLIERS
• 5.11 PATENT ANALYSIS
  • 5.11.1 PATENT PUBLICATION TRENDS FOR PATIENT REGISTRY SOFTWARE MARKET
  • 5.11.2 JURISDICTION ANALYSIS: TOP APPLICANT COUNTRIES FOR PATIENT REGISTRY SOFTWARE
  • 5.11.3 MAJOR PATENTS IN PATIENT REGISTRY SOFTWARE MARKET
• 5.12 KEY STAKEHOLDERS & BUYING CRITERIA
  • 5.12.1 KEY STAKEHOLDERS IN BUYING PROCESS
  • 5.12.2 KEY BUYING CRITERIA
• 5.13 END-USER ANALYSIS
  • 5.13.1 UNMET NEEDS
  • 5.13.2 END-USER EXPECTATIONS
• 5.14 KEY CONFERENCES & EVENTS, 2025-2026
• 5.15 CASE STUDY ANALYSIS
• 5.16 INVESTMENT & FUNDING SCENARIO
• 5.17 BUSINESS MODEL ANALYSIS
• 5.18 IMPACT OF AI/GEN AI ON PATIENT REGISTRY SOFTWARE MARKET
  • 5.18.1 TOP USE CASES & MARKET POTENTIAL
  • 5.18.2 KEY USE CASES
  • 5.18.3 CASE STUDIES OF AI/GENERATIVE AI IMPLEMENTATION
    • 5.18.3.1 Case study: AI-powered data summarization improves registry utilization efficiency
  • 5.18.4 ELECTRONIC HEALTH RECORD (EHR) MARKET
  • 5.18.5 REAL WORLD EVIDENCE (RWE) MARKET
  • 5.18.6 USER READINESS AND IMPACT ASSESSMENT
    • 5.18.6.1 User readiness
      • 5.18.6.1.1 Hospitals & research networks
    • 5.18.6.2 Impact assessment
      • 5.18.6.2.1 Hospitals & academic research institutes
        • 5.18.6.2.1.1 Implementation
        • 5.18.6.2.1.2 Impact
• 5.19 IMPACT OF 2025 US TARIFFS ON PATIENT REGISTRY SOFTWARE MARKET
  • 5.19.1 INTRODUCTION
  • 5.19.2 KEY TARIFF RATES
  • 5.19.3 PRICE IMPACT ANALYSIS
    • 5.19.3.1 Cloud hosting infrastructure
    • 5.19.3.2 AI & analytics modules
    • 5.19.3.3 Offshore development & support services
  • 5.19.4 IMPACT ON COUNTRY/REGION
    • 5.19.4.1 US
    • 5.19.4.2 Europe
    • 5.19.4.3 Asia Pacific
  • 5.19.5 IMPACT ON END-USE INDUSTRIES
    • 5.19.5.1 For-profit registries
    • 5.19.5.2 Nonprofit registries
    • 5.19.5.3 Government & third-party administrators
    • 5.19.5.4 Others

6 PATIENT REGISTRY SOFTWARE MARKET, BY REGISTRY TYPE

• 6.1 INTRODUCTION
• 6.2 DISEASE REGISTRIES
  • 6.2.1 DIABETES REGISTRIES
    • 6.2.1.1 Need to monitor disease prevalence, treatment adherence, and long-term complications to boost adoption
  • 6.2.2 CARDIOVASCULAR REGISTRIES
    • 6.2.2.1 Ability of cardiovascular registries to enable healthcare systems to benchmark care quality and identify treatment gaps to boost growth
  • 6.2.3 CANCER REGISTRIES
    • 6.2.3.1 Critical tools for understanding cancer epidemiology and evaluating screening programs to drive market
  • 6.2.4 RARE DISEASE REGISTRIES
    • 6.2.4.1 Essential tools for advancing knowledge about rare diseases to support market growth
  • 6.2.5 ASTHMA REGISTRIES
    • 6.2.5.1 Improving asthma management and reducing exacerbations to fuel growth
  • 6.2.6 CHRONIC KIDNEY REGISTRIES
    • 6.2.6.1 Ability of registries to collect detailed data on disease progression, lab results, and treatment adherence to boost adoption
  • 6.2.7 ORTHOPEDIC REGISTRIES
    • 6.2.7.1 Ability to monitor implant performance, surgical outcomes, and complication rates to drive growth
  • 6.2.8 IMMUNIZATION REGISTRIES
    • 6.2.8.1 Strengthening vaccine coverage and safety monitoring to propel market
  • 6.2.9 BIRTH DEFECT REGISTRIES
    • 6.2.9.1 Need to track and prevent congenital anomalies through birth defect registries to propel market growth
  • 6.2.10 OTHER DISEASE REGISTRIES
• 6.3 PRODUCT REGISTRIES
  • 6.3.1 MEDICAL DEVICE REGISTRIES
    • 6.3.1.1 Ability of these registries to enhance safety, performance monitoring, and regulatory compliance to boost growth
  • 6.3.2 DRUG REGISTRIES
    • 6.3.2.1 Ability to support long-term safety, real-world evidence, and optimal therapy use to propel growth

7 PATIENT REGISTRY SOFTWARE MARKET, BY PRODUCT

• 7.1 INTRODUCTION
• 7.2 DIRECT-TO-PATIENT (PATIENT-RECORDED) REGISTRIES
  • 7.2.1 INCREASING PATIENT ENGAGEMENT AND DEMAND FOR SELF-REPORTED DATA TO BOOST MARKET GROWTH
• 7.3 SITE-BASED/CLINICAL DATA (PROVIDER-RECORDED) REGISTRIES
  • 7.3.1 GROWING NEED FOR ACCURATE, CLINICIAN-VERIFIED DATA AND SEAMLESS EHR INTEGRATION TO SUPPORT GROWTH

8 PATIENT REGISTRY SOFTWARE MARKET, BY USE CASE

• 8.1 INTRODUCTION
• 8.2 MEDICAL RESEARCH & CLINICAL STUDIES
  • 8.2.1 GROWING NEED TO LEVERAGE REGISTRIES TO ENHANCE REAL-WORLD EVIDENCE AND CLINICAL TRIAL EFFICIENCY TO FUEL GROWTH
• 8.3 QUALITY IMPROVEMENT
  • 8.3.1 ADVANTAGES SUCH AS EVIDENCE-BASED PRACTICE AND PERFORMANCE BENCHMARKING TO DRIVE SEGMENTAL GROWTH
• 8.4 PATIENT CARE MANAGEMENT
  • 8.4.1 ABILITY TO EMPOWER PROACTIVE CHRONIC DISEASE MANAGEMENT THROUGH CENTRALIZED REGISTRIES TO SUPPORT GROWTH
• 8.5 POPULATION HEALTH
  • 8.5.1 EXPANDING ROLE OF PATIENT MANAGEMENT SYSTEMS IN DRIVING DIGITAL TRANSFORMATION TO CONTRIBUTE TO GROWTH
• 8.6 POINT-OF-CARE SUPPORT
  • 8.6.1 NEED FOR PERSONALIZED TREATMENT PLANS AND SHARED DECISION-MAKING TO DRIVE EFFICIENCY AND QUALITY IN HEALTHCARE
• 8.7 PUBLIC HEALTH SURVEILLANCE
  • 8.7.1 ABILITY OF REGISTRIES TO ENHANCE PREPAREDNESS AND RESPONSE CAPABILITIES TO DRIVE SEGMENTAL GROWTH
• 8.8 PATIENT SELF-CARE
  • 8.8.1 GROWING EMPHASIS ON PATIENT EMPOWERMENT AND SELF-MANAGEMENT TO PROPEL GROWTH
• 8.9 PATIENT ENGAGEMENT
  • 8.9.1 ADVANTAGES SUCH AS BETTER DATA ACCURACY AND MORE MEANINGFUL OUTCOMES TO BOOST GROWTH
• 8.10 OTHER USE CASES

9 PATIENT REGISTRY SOFTWARE MARKET, BY DEPLOYMENT

• 9.1 INTRODUCTION
• 9.2 ON-PREMISE MODELS
  • 9.2.1 GROWING DEMAND FOR SECURITY, CONTROL, AND COMPLIANCE TO DRIVE MARKET GROWTH
• 9.3 CLOUD-BASED MODELS
  • 9.3.1 SCALABILITY, INTEROPERABILITY, AND COST-EFFECTIVENESS OF CLOUD-BASED MODELS TO DRIVE GROWTH

10 PATIENT REGISTRY SOFTWARE MARKET, BY END USER

• 10.1 INTRODUCTION
• 10.2 FOR-PROFIT REGISTRIES
  • 10.2.1 PHARMACEUTICAL, BIOTECHNOLOGY, AND MEDTECH COMPANIES
    • 10.2.1.1 Need for robust evidence generation, enhanced patient safety, and competitive differentiation to drive adoption
  • 10.2.2 HEALTHCARE PAYERS
    • 10.2.2.1 Need to improve population health management, control costs, and assess treatment value to drive demand
  • 10.2.3 HEALTHCARE PROVIDERS
    • 10.2.3.1 Hospitals
      • 10.2.3.1.1 Ability of registries to help hospitals collect detailed data on procedures, outcomes, and complications to boost market
    • 10.2.3.2 Clinics & outpatient settings
      • 10.2.3.2.1 Ability of registries to enable data-driven decision-making and streamlined documentation to drive demand
    • 10.2.3.3 Other healthcare providers
• 10.3 NONPROFIT REGISTRIES
  • 10.3.1 MEDICAL SPECIALTY SOCIETIES
    • 10.3.1.1 Advantages such as defined best practices and improved care delivery to propel growth
  • 10.3.2 PATIENT ORGANIZATIONS
    • 10.3.2.1 Importance of facilitating clinical trial recruitment and fostering collaboration with researchers to support growth
• 10.4 GOVERNMENT & THIRD-PARTY ADMINISTRATORS
  • 10.4.1 ABILITY OF GOVERNMENT-RUN REGISTRIES TO EVALUATE SUCCESS OF HEALTHCARE INITIATIVES TO FUEL MARKET
• 10.5 OTHER END USERS

11 PATIENT REGISTRY SOFTWARE MARKET, BY REGION

• 11.1 INTRODUCTION
• 11.2 NORTH AMERICA
  • 11.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
  • 11.2.2 US
    • 11.2.2.1 US to dominate global market for patient registry software
  • 11.2.3 CANADA
    • 11.2.3.1 Government investment, collaborative initiatives, and strong push to standardize rare disease registries to drive growth
• 11.3 EUROPE
  • 11.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
  • 11.3.2 UK
    • 11.3.2.1 Growing incidence of cancer to drive market growth
  • 11.3.3 GERMANY
    • 11.3.3.1 National rollout of e-patient files and rare disease registries to strengthen patient care and research
  • 11.3.4 FRANCE
    • 11.3.4.1 Growing patient registry adoption with national data platforms and rare disease initiatives to support market growth
  • 11.3.5 ITALY
    • 11.3.5.1 Growing number of national networks and disease-specific registries to drive growth
  • 11.3.6 SPAIN
    • 11.3.6.1 Growing need to address rising chronic and cardiovascular disease prevalence to drive adoption
  • 11.3.7 REST OF EUROPE
• 11.4 ASIA PACIFIC
  • 11.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
  • 11.4.2 JAPAN
    • 11.4.2.1 Japan's aging population and advanced digital strategies to drive growth in patient registry software market
  • 11.4.3 CHINA
    • 11.4.3.1 Robust national registries and expanding pharmaceutical approvals to drive patient registry software market
  • 11.4.4 INDIA
    • 11.4.4.1 Digital health advances to boost India's patient registry software market
  • 11.4.5 REST OF ASIA PACIFIC
• 11.5 LATIN AMERICA
  • 11.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
  • 11.5.2 BRAZIL
    • 11.5.2.1 Brazil to dominate patient registry software market in Latin America
  • 11.5.3 MEXICO
    • 11.5.3.1 Increase in focus of digital health to boost market growth
  • 11.5.4 REST OF LATIN AMERICA
• 11.6 MIDDLE EAST & AFRICA
  • 11.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
  • 11.6.2 GCC COUNTRIES
    • 11.6.2.1 Rising healthcare investments to fuel uptake
  • 11.6.3 REST OF MIDDLE EAST & AFRICA

12 COMPETITIVE LANDSCAPE

• 12.1 OVERVIEW
• 12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
  • 12.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN PATIENT REGISTRY SOFTWARE MARKET
• 12.3 REVENUE ANALYSIS, 2020-2024
• 12.4 MARKET SHARE ANALYSIS, 2024
• 12.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
  • 12.5.1 STARS
  • 12.5.2 EMERGING LEADERS
  • 12.5.3 PERVASIVE PLAYERS
  • 12.5.4 PARTICIPANTS
  • 12.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024
    • 12.5.5.1 Company footprint
    • 12.5.5.2 Region footprint
    • 12.5.5.3 Product footprint
    • 12.5.5.4 Use case footprint
    • 12.5.5.5 Registry type footprint
    • 12.5.5.6 Deployment footprint
    • 12.5.5.7 End-user footprint
• 12.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
  • 12.6.1 PROGRESSIVE COMPANIES
  • 12.6.2 RESPONSIVE COMPANIES
  • 12.6.3 DYNAMIC COMPANIES
  • 12.6.4 STARTING BLOCKS
  • 12.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024
    • 12.6.5.1 Detailed list of key startups/SMEs
    • 12.6.5.2 Competitive benchmarking of startups/Smes
• 12.7 COMPANY VALUATION & FINANCIAL METRICS
  • 12.7.1 FINANCIAL METRICS
  • 12.7.2 COMPANY VALUATION
• 12.8 BRAND/SOFTWARE COMPARISON
• 12.9 COMPETITIVE SCENARIO
  • 12.9.1 PRODUCT LAUNCHES, APPROVALS, UPGRADES, AND ENHANCEMENTS
  • 12.9.2 DEALS
  • 12.9.3 OTHER DEVELOPMENTS

13 COMPANY PROFILES

• 13.1 KEY PLAYERS
  • 13.1.1 IBM
    • 13.1.1.1 Business overview
    • 13.1.1.2 Products offered
    • 13.1.1.3 Recent developments
      • 13.1.1.3.1 Product enhancements
    • 13.1.1.4 MnM view
      • 13.1.1.4.1 Right to win
      • 13.1.1.4.2 Strategic choices
      • 13.1.1.4.3 Weaknesses & competitive threats
  • 13.1.2 IQVIA HOLDINGS INC.
    • 13.1.2.1 Business overview
    • 13.1.2.2 Products offered
    • 13.1.2.3 Recent developments
      • 13.1.2.3.1 Deals
    • 13.1.2.4 MnM view
      • 13.1.2.4.1 Right to win
      • 13.1.2.4.2 Strategic choices
      • 13.1.2.4.3 Weaknesses & competitive threats
  • 13.1.3 HEALTH CATALYST, INC.
    • 13.1.3.1 Business overview
    • 13.1.3.2 Products offered
    • 13.1.3.3 Recent developments
      • 13.1.3.3.1 Product approvals
      • 13.1.3.3.2 Deals
      • 13.1.3.3.3 Other developments
    • 13.1.3.4 MnM view
      • 13.1.3.4.1 Right to win
      • 13.1.3.4.2 Strategic choices
      • 13.1.3.4.3 Weaknesses & competitive threats
  • 13.1.4 ORACLE
    • 13.1.4.1 Business overview
    • 13.1.4.2 Products offered
    • 13.1.4.3 Recent developments
      • 13.1.4.3.1 Deals
    • 13.1.4.4 MnM view
      • 13.1.4.4.1 Right to win
      • 13.1.4.4.2 Strategic choices
      • 13.1.4.4.3 Weaknesses & competitive threats
  • 13.1.5 UNITEDHEALTH GROUP
    • 13.1.5.1 Business overview
    • 13.1.5.2 Products offered
    • 13.1.5.3 Recent developments
      • 13.1.5.3.1 Deals
    • 13.1.5.4 MnM view
      • 13.1.5.4.1 Right to win
      • 13.1.5.4.2 Strategic choices
      • 13.1.5.4.3 Weaknesses & competitive threats
  • 13.1.6 CONDUENT INCORPORATED
    • 13.1.6.1 Business overview
    • 13.1.6.2 Products offered
    • 13.1.6.3 Recent developments
      • 13.1.6.3.1 Deals
  • 13.1.7 ELEKTA
    • 13.1.7.1 Business overview
    • 13.1.7.2 Products offered
    • 13.1.7.3 Recent developments
      • 13.1.7.3.1 Deals
  • 13.1.8 NEC CORPORATION (NEC SOFTWARE SOLUTIONS UK LIMITED)
    • 13.1.8.1 Business overview
    • 13.1.8.2 Products offered
  • 13.1.9 DASSAULT SYSTEMES (MEDIDATA)
    • 13.1.9.1 Business overview
    • 13.1.9.2 Products offered
    • 13.1.9.3 Recent developments
      • 13.1.9.3.1 Product launches
      • 13.1.9.3.2 Deals
  • 13.1.10 EVIDENTIQ (DACIMA SOFTWARE INC.)
    • 13.1.10.1 Business overview
    • 13.1.10.2 Products offered
    • 13.1.10.3 Recent developments
      • 13.1.10.3.1 DEALS
  • 13.1.11 MRO (FIGMD, INC.)
    • 13.1.11.1 Business overview
    • 13.1.11.2 Products offered
    • 13.1.11.3 Recent developments
      • 13.1.11.3.1 Deals
      • 13.1.11.3.2 Other developments
  • 13.1.12 IMAGETREND
    • 13.1.12.1 Business overview
    • 13.1.12.2 Products offered
    • 13.1.12.3 Recent developments
      • 13.1.12.3.1 Product upgrades
      • 13.1.12.3.2 Deals
  • 13.1.13 GLOBAL VISION TECHNOLOGIES, INC.
    • 13.1.13.1 Business overview
    • 13.1.13.2 Products offered
    • 13.1.13.3 Recent developments
      • 13.1.13.3.1 Other developments
  • 13.1.14 SYNEOS HEALTH
    • 13.1.14.1 Business overview
    • 13.1.14.2 Products offered
    • 13.1.14.3 Recent developments
      • 13.1.14.3.1 Deals
  • 13.1.15 VERADIGM LLC
    • 13.1.15.1 Business overview
    • 13.1.15.2 Products offered
    • 13.1.15.3 Recent developments
      • 13.1.15.3.1 Product launches
      • 13.1.15.3.2 Deals
  • 13.1.16 ESO
    • 13.1.16.1 Business overview
    • 13.1.16.2 Products offered
    • 13.1.16.3 Recent developments
      • 13.1.16.3.1 Deals
  • 13.1.17 ORDINAL DATA INC.
    • 13.1.17.1 Business overview
    • 13.1.17.2 Products offered
  • 13.1.18 CEDARON MEDICAL
    • 13.1.18.1 Business overview
    • 13.1.18.2 Products offered
  • 13.1.19 FIVOS HEALTH
    • 13.1.19.1 Business overview
    • 13.1.19.2 Products offered
    • 13.1.19.3 Recent developments
      • 13.1.19.3.1 Deals
  • 13.1.20 ACROSS HEALTHCARE
    • 13.1.20.1 Business overview
    • 13.1.20.2 Products offered
    • 13.1.20.3 Recent developments
      • 13.1.20.3.1 Deals
• 13.2 OTHER PLAYERS
  • 13.2.1 VERANA HEALTH
  • 13.2.2 PULSE INFOFRAME INC.
  • 13.2.3 AMPLITUDE CLINICAL OUTCOMES
  • 13.2.4 NPHASE, INC. (REDCAP CLOUD)
  • 13.2.5 OM1

14 APPENDIX

• 14.1 DISCUSSION GUIDE
• 14.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 14.3 CUSTOMIZATION OPTIONS
• 14.4 RELATED REPORTS
• 14.5 AUTHOR DETAILS